We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CAMELOT

News List

Sagent Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 americanpharmaceuticalreview
November 24, 2020
Sagent Pharmaceuticals, a Nichi-Iko Group Company, has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of COVID-19 in high-risk outpatients and has begun enrolling patients.
Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment pharmaceutical-business-review
November 17, 2020
Sagent Pharmaceuticals announced that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of Covid-19 in high-risk outpatients and has begun enrolling patients.